Lyogenesis Holdings
About
LyGenesis is a clinical-stage biotechnology company developing a novel cell therapy platform that uses patients' lymph nodes as bioreactors to grow functioning ectopic organs. Their therapies target unmet needs in diseases such as end-stage liver disease, Type 1 diabetes, end-stage renal disease, and aging. This approach aims to revolutionize treatment by creating a less invasive and more economical alternative to traditional organ transplantation.
Comments
No comments yet. Be the first to share your take.
Frequently asked
What type of investor is Lyogenesis Holdings?
LyGenesis is a clinical-stage biotechnology company developing a novel cell therapy platform that uses patients' lymph nodes as bioreactors to grow functioning ectopic organs. Their therapies target unmet needs in diseases such as end-stage liver disease, Type 1 diabetes, end-stage renal disease, and aging. This approach aims to revolutionize treatment by creating a less invasive and more economic…
What kind of firm is Lyogenesis Holdings?
Lyogenesis Holdings is a Venture Capital.
Where is Lyogenesis Holdings based?
Lyogenesis Holdings is based in Pittsburgh, USA.
What sectors does Lyogenesis Holdings focus on?
Lyogenesis Holdings focuses on Biotechnology, Healthcare, Regenerative Medicine.